NASDAQ:EKSO Ekso Bionics (EKSO) Stock Price, News & Analysis → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Free EKSO Stock Alerts $1.36 -0.06 (-4.23%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.28▼$1.4650-Day Range$1.32▼$2.5052-Week Range$0.62▼$3.13Volume357,285 shsAverage Volume247,104 shsMarket Capitalization$24.34 millionP/E RatioN/ADividend YieldN/APrice Target$9.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Ekso Bionics alerts: Email Address Ekso Bionics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside580.1% Upside$9.25 Price TargetShort InterestHealthy0.62% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.49) to ($0.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.71 out of 5 starsMedical Sector474th out of 939 stocksGeneral Industrial Machinery, Industry3rd out of 10 stocks 3.5 Analyst's Opinion Consensus RatingEkso Bionics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.25, Ekso Bionics has a forecasted upside of 580.1% from its current price of $1.36.Amount of Analyst CoverageEkso Bionics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.62% of the outstanding shares of Ekso Bionics have been sold short.Short Interest Ratio / Days to CoverEkso Bionics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ekso Bionics has recently decreased by 23.36%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEkso Bionics does not currently pay a dividend.Dividend GrowthEkso Bionics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EKSO. Previous Next 3.0 News and Social Media Coverage News SentimentEkso Bionics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Ekso Bionics this week, compared to 1 article on an average week.Search Interest39 people have searched for EKSO on MarketBeat in the last 30 days. This is an increase of 680% compared to the previous 30 days.MarketBeat Follows10 people have added Ekso Bionics to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ekso Bionics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.50% of the stock of Ekso Bionics is held by insiders.Percentage Held by InstitutionsOnly 6.42% of the stock of Ekso Bionics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ekso Bionics are expected to grow in the coming year, from ($0.49) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ekso Bionics is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ekso Bionics is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEkso Bionics has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About Ekso Bionics Stock (NASDAQ:EKSO)Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therap, an adjustable and lower-limb powered exoskeleton; and Ekso Indego Personal, a powered lower limb orthosis. It has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in San Rafael, California.Read More EKSO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EKSO Stock News HeadlinesMarch 23, 2024 | americanbankingnews.comEkso Bionics (NASDAQ:EKSO) Upgraded to Hold at StockNews.comMarch 19, 2024 | finanznachrichten.deMedical Robots Market Worth $33.8 billion | MarketsandMarketsMarch 29, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 16, 2024 | uk.investing.comEkso Bionics director Lathan Corinna buys shares worth $15.5kMarch 11, 2024 | finance.yahoo.comGlobal Exoskeleton Research Report 2023: From Concept to Reality - Advancements and Challenges in Exoskeleton Developments with Forecasts to 2035March 6, 2024 | marketwatch.comEkso Bionics Shares Fall on Delayed CMS Payment DeterminationMarch 6, 2024 | finance.yahoo.comEkso Bionics Holdings Full Year 2023 Earnings: EPS Misses ExpectationsMarch 5, 2024 | finanznachrichten.deEkso Bionics Holdings, Inc.: Ekso Bionics Reports Record Annual Revenue of $18.3 MillionMarch 29, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 5, 2024 | seekingalpha.comEkso Bionics Holdings, Inc. (EKSO) Q4 2023 Earnings Call TranscriptMarch 5, 2024 | finance.yahoo.comEkso Bionics Holdings, Inc. (NASDAQ:EKSO) Q4 2023 Earnings Call TranscriptMarch 4, 2024 | investorplace.comEKSO Stock Earnings: Ekso Bionics Holdings Misses EPS, Beats Revenue for Q4 2023March 4, 2024 | benzinga.comRecap: Ekso Bionics Holdings Q4 EarningsMarch 4, 2024 | globenewswire.comEkso Bionics Reports Record Annual Revenue of $18.3 MillionMarch 3, 2024 | msn.comEkso Bionics Holdings Q4 Earnings PreviewMarch 3, 2024 | markets.businessinsider.comEkso Bionics earnings preview: what to expectFebruary 26, 2024 | finance.yahoo.comEkso Bionics to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024February 24, 2024 | msn.comEkso Bionics Holdings (EKSO) Price Target Increased by 11.11% to 10.20February 21, 2024 | wsj.comEkso Bionics Holdings Inc.February 6, 2024 | msn.comHere's Why Ekso Bionics (EKSO) Is a Great 'Buy the Bottom' Stock NowJanuary 25, 2024 | benzinga.com(EKSO) - Analyzing Ekso Bionics Holdings's Short InterestJanuary 23, 2024 | investing.comEkso Bionics Holdings Inc (EKSO)January 23, 2024 | finance.yahoo.comWhen Will Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Become Profitable?January 11, 2024 | marketwatch.comEkso Bionics Shares Down After Announcing Stock OfferingJanuary 11, 2024 | msn.comEkso Bionics announces $4.6M registered direct offeringJanuary 11, 2024 | finance.yahoo.comEkso Bionics Announces $4.6 Million Registered Direct OfferingJanuary 9, 2024 | finanznachrichten.deEkso Bionics Holdings, Inc.: Ekso Bionics Launches GaitCoach Software for EksoNRSee More Headlines Receive EKSO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/04/2024Today3/29/2024Next Earnings (Estimated)4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry General industrial machinery, Sub-IndustryN/A Current SymbolNASDAQ:EKSO Previous SymbolOTCMKTS:EKSOD CUSIPN/A CIK1549084 Webwww.eksobionics.com Phone(510) 984-1761Fax510-927-2647Employees72Year FoundedN/APrice Target and Rating Average Stock Price Target$9.25 High Stock Price Target$9.25 Low Stock Price Target$9.25 Potential Upside/Downside+580.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,200,000.00 Net Margins-83.14% Pretax Margin-83.14% Return on Equity-90.80% Return on Assets-46.34% Debt Debt-to-Equity Ratio0.38 Current Ratio2.49 Quick Ratio1.87 Sales & Book Value Annual Sales$18.28 million Price / Sales1.33 Cash FlowN/A Price / Cash FlowN/A Book Value$0.85 per share Price / Book1.60Miscellaneous Outstanding Shares17,900,000Free Float16,560,000Market Cap$24.34 million OptionableOptionable Beta1.65 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Scott G. Davis (Age 54)CEO & Director Comp: $535.8kMr. Jerome Wong (Age 50)Corporate Controller, Corporate Secretary & CFO Comp: $356.81kMr. Jason C. JonesChief Operating OfficerMs. Rachael AndersonGlobal Director of Marketing & Strategic GrowthMr. Anthony PrattVice President of SalesMs. Ann CooksonHuman Resources DirectorMs. Foon Lim ChweePresident of APACMr. Stephan AderholdSenior VP & GM of EMEAMore ExecutivesKey CompetitorsLipocineNASDAQ:LPCNExagenNASDAQ:XGNAgape ATPNASDAQ:ATPCLisata TherapeuticsNASDAQ:LSTAStreamline Health SolutionsNASDAQ:STRMView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCBought 8,000 shares on 2/15/2024Ownership: 0.000%Kent Lake Capital LLCBought 141,158 shares on 2/14/2024Ownership: 0.951%Essex Investment Management Co. LLCSold 62,858 shares on 2/8/2024Ownership: 1.062%Simplex Trading LLCBought 5,000 shares on 2/2/2024Ownership: 0.000%Strategic Wealth Investment Group LLCBought 9,285 shares on 1/16/2024Ownership: 0.365%View All Insider TransactionsView All Institutional Transactions EKSO Stock Analysis - Frequently Asked Questions Should I buy or sell Ekso Bionics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EKSO shares. View EKSO analyst ratings or view top-rated stocks. What is Ekso Bionics' stock price target for 2024? 1 brokers have issued twelve-month target prices for Ekso Bionics' shares. Their EKSO share price targets range from $9.25 to $9.25. On average, they predict the company's stock price to reach $9.25 in the next twelve months. This suggests a possible upside of 580.1% from the stock's current price. View analysts price targets for EKSO or view top-rated stocks among Wall Street analysts. How have EKSO shares performed in 2024? Ekso Bionics' stock was trading at $2.50 at the beginning of the year. Since then, EKSO stock has decreased by 45.6% and is now trading at $1.36. View the best growth stocks for 2024 here. When is Ekso Bionics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our EKSO earnings forecast. How were Ekso Bionics' earnings last quarter? Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) posted its earnings results on Monday, March, 4th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.11. The firm earned $4.85 million during the quarter, compared to analyst estimates of $4.80 million. Ekso Bionics had a negative net margin of 83.14% and a negative trailing twelve-month return on equity of 90.80%. During the same quarter last year, the company earned ($0.24) earnings per share. When did Ekso Bionics' stock split? Ekso Bionics's stock reverse split on the morning of Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 4th 2016. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What guidance has Ekso Bionics issued on next quarter's earnings? Ekso Bionics updated its fourth quarter 2023 earnings guidance on Thursday, January, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.7 million-$4.9 million, compared to the consensus revenue estimate of $4.6 million. What other stocks do shareholders of Ekso Bionics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ekso Bionics investors own include Organigram (OGI), Gran Tierra Energy (GTE), KushCo (KSHB), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI) and ADMA Biologics (ADMA). Who are Ekso Bionics' major shareholders? Ekso Bionics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Essex Investment Management Co. LLC (1.06%), Kent Lake Capital LLC (0.95%), Strategic Wealth Investment Group LLC (0.37%), Citadel Advisors LLC (0.00%), Simplex Trading LLC (0.00%) and FNY Investment Advisers LLC (0.00%). Insiders that own company stock include Jason C Jones, Jerome Wong, John Glenn, Scott G Davis and Steven Sherman. View institutional ownership trends. How do I buy shares of Ekso Bionics? Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EKSO) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaOnly a fool would buy Nvidia today… Porter & CompanyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ekso Bionics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.